Metastatic melanoma was the first malignancy in which immune checkpoint inhibitors
demonstrated their successful efficacy. Currently, the knowledge on the interaction between …

The role of vitamin D in melanoma is still controversial. Although several Authors described
a correlation between vitamin D deficiency and poor survival in metastatic melanoma …

Background Ipilimumab improves survival in patients with advanced melanoma. The activity
and safety of ipilimumab outside of a clinical trial was assessed in an expanded access …

Background Therapeutic chances for metastatic melanoma have consistently changed over
the last years with the advent of antibodies targeting the programmed cell death protein-1 …

Background Mucosal melanoma is an extremely rare and aggressive malignancy that often
remains undetected until it reaches an advanced stage, when effective treatment options are …

Patients with melanoma brain metastases have a poor prognosis and historically have been
excluded from clinical trials. The Expanded Access Program (EAP) provided an opportunity …

Background Elderly patients with metastatic melanoma have different disease
characteristics and a poorer prognosis than younger patients. Data from clinical trials and …

In melanoma, the adaptative cell response to BRAF inhibitors includes altered patterns of
cytokine production contributing to tumor progression and drug resistance. Among the …

Background Clinical response to MAPK inhibitors in metastatic melanoma patients is
heterogeneous for reasons still needing to be elucidated. As the patient immune activity …

Background Obesity is a risk factor for malignancy; however, its prognostic role in patients
with metastatic melanoma is controversial. We aim to investigate the prognostic role of body …